TECTONICAbbott Coronary IVL System for Calcified Coronary Arteries
Experimental
Arterial Occlusive Diseases+5
+ Arteriosclerosis
+ Cardiovascular Diseases
Treatment Study
Summary
Study start date: April 1, 2025
Actual date on which the first participant was enrolled.This study is focused on evaluating a new medical device called the Abbott Coronary Intravascular Lithotripsy (IVL) System, designed to treat patients with severely calcified and narrowed coronary arteries. These arteries are crucial as they supply blood to the heart, and severe calcification can lead to significant health issues. The study aims to assess how safe and effective this device is in preparing these arteries for a stent, a small tube used to keep the artery open. The study involves 335 participants across various locations in the United States. This research is important as it could lead to improved treatments for patients with challenging coronary artery conditions. Participants in the study will undergo a procedure where the Abbott Coronary IVL System is used to treat their coronary arteries. This device uses a method similar to breaking up kidney stones, targeting the calcified areas to make it easier to place a stent. The study will collect data on the safety of the procedure and how well it works by comparing the outcomes to established goals from previous medical studies. By participating, individuals contribute to understanding whether this new approach could be a reliable option for many patients in the future. The study is conducted under strict regulations to ensure participant safety and is a step towards gaining approval for wider use of the device.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.335 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Over 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.One single intervention group is designated in this study
This study does not include a placebo group
Treatment Groups
Group I
ExperimentalStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 41 locations
Arkansas Heart Hospital
Little Rock, United StatesKaiser Permanente - San Francisco
San Francisco, United StatesMedStar Washington Hospital Center
Washington D.C., United States